Fresenius presents figures
| Reading time: 2 minutes
Bad Homburg (dpa) – In success spoiled health company Fresenius increase the problems. If the DAX company today presents the results for the third quarter, investors will have critical questions. Due to headwinds at the dialysis subsidiary Fresenius Medical Care (FMC) and in the business with clinics, Fresenius was recently more skeptical about 2018. In terms of sales and profits, forecasts are only to be reached at the lower end of the range. FMC had to lower the forecast. The shares broke in.
Clarity about Akorn could provide good news. Fresenius wanted to take over the US drug manufacturer, but blew off the billion-dollar deal, as Akorn drug tests have falsified. A US court gave Fresenius the right to call the Americans. Fresenius could now comment on when to expect a decision.
Fresenius has already announced preliminary figures for the third quarter: According to this, sales are expected to increase by 3 percent to 8.2 billion euros and earnings adjusted for special items by 8 percent to 455 million euros. While liquid medicine businesses are droning like infusions, less profitable treatments are becoming noticeable in the clinics. Even more serious is the situation at FMC, where declines are expected in the third quarter, partly because the US core market is weakening.
Communication Fresenius on the forecast
Message FMC on forecast